Prognostic Model of Elderly Hodgkin Lymphoma in China

NCT07374068 · tracked via the Priya Life Science China tracker

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Phase

Observational

Started

2025-12-09

Last updated

2026-01-28

Condition(s) studied

Hodgkin Lymphoma

Study summary

This multicenter observational cohort study is based on a patient registry designed to systematically collect uniform real-world clinical data from elderly patients with Hodgkin lymphoma (HL) in China. The registry captures demographic characteristics, disease features, laboratory parameters, treatment patterns, and longitudinal survival outcomes to support predefined scientific objectives.

The primary analysis uses retrospectively collected registry data, with prospectively accrued data incorporated for external validation of a prognostic prediction model. This registry-based study aims to improve risk stratification and inform individualized clinical decision-making for elderly patients with HL in routine clinical practice.

Eligibility

Sex

ALL

Min age

60 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Age ≥60 years * Histologically confirmed Hodgkin lymphoma, including classical Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma * Treatment-naïve patients who have not received prior anti-Hodgkin lymphoma therapy * Availability of complete clinical, pathological, and follow-up data Exclusion Criteria: * Presence of other malignant tumors * Severe hepatic or renal dysfunction (Child-Pugh class C or estimated glomerular filtration rate \<30 mL/min) * Missing more than 20% of required clinical data

Primary outcome measure(s)

Overall Survival (OS) — From date of diagnosis until death from any cause, assessed up to 60 months.
Overall survival (OS) is defined as the time from diagnosis to death from any cause.

Trial sites (1)

Facility	City	Region	Status
Tianjin Cancer Hospital	Tianjin	Tianjin Municipality

More Tianjin Medical University Cancer Institute and Hospital trials in China

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer Recruiting

Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma Active, not recruiting

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors Recruiting

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer Recruiting

A Pan-Cancer Retrospective Study on the Relationship Between Tumor Microenvironment Composition and Efficacy of Antibody-Based Antitumor Therapy Active, not recruiting

Other trials for the same condition

CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma Active, not recruiting

The Pathogenesis and Prognostic Factors of Lymphoma Recruiting

PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma Starting soon

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) Recruiting

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07374068 on ClinicalTrials.gov ↗ ← All trials in China